Skip to main content
. 2023 Jun 29;129(3):551–562. doi: 10.1038/s41416-023-02319-6

Fig. 6. Safety evaluation of CAR-modified PMs in combination with oxaliplatin for solid tumours.

Fig. 6

a Hematoxylin–eosin (H&E) staining of the heart, liver, spleen, lung, kidney, and tumour in each group of mice. b Expression of alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), and creatinine (Cr) in peripheral blood of mice serum. c Body-weight changes in mice receiving different treatment. d Representative in vivo images (IVIS) and quantification of luciferase in mice organs.